comprise enhanced receptor potency, prolonged receptor residency time, greater Background -In a previous single dosing tissue retention, and a longer elimination comparison between fluticasone prohalf life. pionate and budesonide differences in (Thorax 1997;52:55-58) cortisol levels measured at 08.00 hours were observed at doses in excess of 1000 g. Keywords therapy in the treatment of asthma. 1 Increased Methods -Twelve stable asthmatic use of inhaled corticosteroids has focused patients of mean age 29.7 years with forced greater attention on their systemic side effect expiratory volume in one second (FEV 1 ) profiles. Of these systemic effects, adrenal sup-89.0% predicted and mid forced expiratory pression is the most sensitive accessible marker flow (FEF 25-75 ) 58.9% predicted, on 400 currently available. In a previous dose ranging g/day or less of inhaled corticosteroid, study we have revealed significant differences were studied in a double blind, placebo between inhaled fluticasone propionate and controlled, crossover design comparing budesonide in the degree of adrenal supinhaled budesonide and fluticasone pression induced when given as single doses propionate in doses of 250 g, 500 g, and on a microgram equivalent basis in asthmatic 1000 g twice daily. Each dose was given patients. 2 These differences between single at 08.00 hours and 22.00 hours for four doses of fluticasone and budesonide can be days by metered dose inhaler with mouth explained by the pharmacological properties of rinsing. Measurements were made of over-fluticasone which has both greater gluconight urinary cortisol excretion and corticoid receptor potency 3 and receptor resplasma cortisol levels at 08.00 hours, 10 idency time 4 than budesonide. However, of hours after the eighth dose.
The mean forced expiratory volume in one laboratory visit at 08.00 hours the following morning. No further steroid or bronchodilator second (FEV 1 ) was 3.07 (0.07) l (89.0 (3.71)% of predicted) and mid forced expiratory flow inhalers were taken until completion of the laboratory visit. ) was 2.49 (0.19) l/s (58.9 (5.1)% of predicted). Haematological and biochemical parameters were normal before entry into the study. All gave written informed consent and 
The subjects attended the laboratory at 07.30 approval for the study was given by the Tayside medical ethics committee. All patients had hours, 10 hours after taking the eighth dose of study drug at each dose level. A cannula was asthma according to the criteria of the American Thoracic Society 10 and were required to inserted into an antecubital fossa vein to allow blood sampling and subjects then rested supine be taking 400 g/day or less of inhaled corticosteroid. The doses of inhaled corticosteroid for 30 minutes. After the rest period blood samples were taken for measurement of serum taken by the 12 subjects were beclomethasone dipropionate 200 g/day (two patients), 300 g/ cortisol levels. The total volume of the overnight 10 hour urine specimen was measured day (one patient), 400 g/day (six patients), budesonide 400 g/day (two patients), and one and aliquots were kept for assay of cortisol and creatinine levels. patient took no inhaled steroids. None had received oral corticosteroids within the preceding three months.
 Serum and urinary cortisol levels were measured using a commercial radioimmunoassay  A double blind, placebo controlled, ran-kit (Incstar, Wokingham, Berkshire, UK). The coefficient of variability (CV) for analytical imdomised crossover design was used with twice daily dosing over four days at each dose level. precision within the assay was 4.5% and between the assays was 8.1%. Urinary creatinine Subjects attended an initial screening visit where FEV 1 and FEF were measured using levels were measured on a Cobas-bio autoanalyser (Roche Products Ltd, Welwyn Garden a Vitalograph Compact spirometer (Vitalograph Ltd, Buckingham, UK), having withheld City, Hertfordshire, UK). The intra-assay CV was 4.55% and interassay was 0.63%. inhaled bronchodilators for eight hours. FEV 1 was checked on each of the study visits and measurements were only made if it was within 15% of the baseline value. Inhaler technique   All data were analysed using a Statgraphics was assessed using an aerosol inhalation monitor (Vitalograph Ltd) and detailed instructions software package (STSC Software Group, Rockville, Maryland, USA). The data were in correct usage were given at each visit. Subjects were then randomised to receive flu-analysed by comparing placebo with both drugs at each dose level using analysis of variance, ticasone propionate (Flixotide metered dose inhaler (MDI), 250 g per actuation, Allen and followed by Duncan's multiple range testing to observe multiple comparisons. 95% confidence Hanburys, Uxbridge, Middlesex, UK) in doses of 250 g, 500 g, and 1000 g twice daily or intervals (CI) for differences between treatments were calculated where significant differbudesonide (Pulmicort MDI, 50 g and 200 g per actuation, Astra Pharmaceuticals, Kings ences were detected. A probability value of p<0.05 (two tailed) was considered significant. Langley, Hertfordshire, UK) in doses of 250 g, 500 g, and 1000 g twice daily, each dose being given sequentially for four days. Randomisation was in balanced blocks with six Results
Fluticasone propionate produced greater supreceiving fluticasone first and six budesonide first. Placebo MDI was given for four days at pression of both 08.00 hour plasma cortisol and overnight urinary cortisol levels than the start of each of the two treatment periods. There was at least a 16 day washout period budesonide ( fig 1) . This effect was evident even at the lowest dose of 250 g twice daily. between the two 12 day drug sequences during which the patients resumed their standard in-Estimated equivalent potency values by log linear interpolation for percentage suppression haled steroid therapy. The aerosol canisters and plastic actuators were masked and placed of 08.00 hour plasma cortisol levels showed a 3.5:1 ratio from comparison of dose-response in identical boxes in order to blind the treatment with respect to the patient. Each treat-curves. In other words, 250 g fluticasone twice daily was equivalent to 875 g budesonide ment box was dispensed by a different person from the investigator to make the study double twice daily.
Fluticasone produced significantly lower blind. Subjects omitted their usual steroid inhaler for the duration of each 12 day sequence 08.00 hour plasma cortisol levels (nmol/l) than budesonide at all three doses ranging from and took their bronchodilator inhaler 15 minutes before the study drug at 08.00 hours and 250 g to 1000 g twice daily. Fluticasone produced significant suppression compared with 22.00 hours. Mouth rinsing was performed after each of two puffs of their study inhaler. placebo at all doses, whereas budesonide did not at any dose. After seven doses at each dose level, immediately before taking the dose at 22.00 hours, Fluticasone also had a greater effect than budesonide on the overnight urinary cortisol/ subjects emptied their bladder and collected all their overnight urine for 10 hours until the creatinine ratio (nmol/mmol) at all three dose levels for both plasma cortisol levels and over- * significant difference between the steroid dose and placebo night urinary cortisol/creatinine ratio (fig 2) .
(p<0.05).
Individual data for urinary free cortisol levels at all doses are shown in fig 3 to illustrate dispersion and outliers. This showed that 21 of 36 measurements for fluticasone and three of 36 for budesonide were below 10 nmol/10 hours (p<0.005). There were no significant differences in FEV 1 after each four day drug sequence which confirms that variation in lung bioavailability of inhaled steroid or asthma control would be unlikely to affect the cortisol results; fluticasone: baseline 2.93 l, F250 2.99 l, F500 3.02 l, F1000 3.03 l; budesonide: baseline 3.01 l, B250 3.03 l, B500 2.96 l, B1000 2.96 l.
Discussion
This study shows that fluticasone propionate causes greater adrenal suppression than budesonide when given on a microgram equivalent basis by metered dose inhaler with repeated twice daily dosing to asthmatic patients across a dose range of 250-1000 g twice daily. A 3.5-fold difference in systemic potency was found between the two drugs which compares with the 5.2-fold difference previously reported by Boorsma et al in normal volunteers for suppression of 08.00 hour cortisol levels.
11 The differential between fluticasone and budesonide is greater with chronic dosing than that fluticasone accentuating its greater glucogroup.bmj.com on June 24, 2017 -Published by http://thorax.bmj.com/ Downloaded from corticoid potency when given with chronic single 1000 g dose produced 6% suppression of plasma cortisol levels compared with 45% dosing. In a chronic dosing evaluation of flusuppression for chronic dosing with 1000 g ticasone 1000 g twice daily against beclotwice daily, representing a seven-fold increase. methasone dipropionate 800 g twice daily At the 500 g level a single dose caused no (Diskhaler) significant adrenal suppression of suppression compared with placebo, whereas plasma cortisol levels was observed with fluchronic dosing with 500 g twice daily proticasone but not beclomethasone, which was duced a 19% fall in 08.00 hour cortisol levels. maintained throughout the 12 weeks of the Our results agree with those of Grahnen et al 8 evaluation.
12 Furthermore, after a further two who reported suppression of plasma cortisol weeks washout there was still detectable sup-(as AUC 0-20 ) of 28% when fluticasone was pression in the fluticasone group, suggesting given as a single dose of 1000 g via a Diskhaler prolonged body retention. Another factor to healthy volunteers compared with 65% when which may partially explain the observed it was given as 1000 g twice daily for three differences between the two drugs is that the and a half days. fluticasone MDI produces greater lung de-
In conclusion, our results demonstrate that position than the budesonide MDI, although the greater glucocorticoid potency of fluthis is based on in vitro data. 13 However, since ticasone than budesonide translates directly patients often have difficulty using MDIs, puinto increased systemic bioactivity as assessed tative differences in deposition may become by adrenal suppression using either plasma or less important in the real life situation. urinary cortisol levels. In fact, the complex Comparison between the results of our pre-interplay between factors including receptor vious single dosing study 2 and the present potency, receptor residency time, tissue rechronic dosing study reveals that this ac-tention, and plasma elimination half life for centuation of the effects of fluticasone results fluticasone and budesonide results in sigin differences between the two drugs being nificantly greater adrenal suppression for fluevident at much lower dose levels with repeated ticasone with repeated administration at doses administration. Indeed, with chronic dosing as low as 250 g twice daily. This highlights differences in suppression of plasma cortisol the necessity for adequate comparative dose levels occurred at a dose of 250 g twice daily, ranging studies of inhaled corticosteroids to whereas with single dosing a difference in characterise fully the dose response replasma cortisol levels was only demonstrated lationships of this important class of drugs. above 1000 g. However, it should be noted 
